Abstract
In the last years, PKC has become an attractive target for the treatment of cancer patients given its widely described role in carcinogenesis and tumor promotion. Despite the extensive research conducted on these phorbol ester receptors there is only limited knowledge about the contribution of each individual PKC isozyme in malignant transformation, mainly due to the different roles of each isozyme and their tissue-specificity. This diversity provides the unique opportunity to develop specific pharmacological agents, but the complex nature of the signaling pathways activated by different PKCs challenges selective drug therapies. Currently, several classes of PKC inhibitors including small molecule kinase inhibitors, biologic modulators, and anti-sense oligonucleotides are being evaluated for the treatment of different cancers where PKC isozymes were found to be deregulated as lung, colon, skin, prostate, and breast malignancies. In this article we will review which PKC isoforms are deregulated in different human cancers and summarize the mechanism of action of some of the major PKC modulators, analyzing the strengths and weaknesses of each one in the clinical setting.
Keywords: Cancer, clinical trials, PKC, tumor promotion, malignant transformation, specific pharmacological agents, anti-sense oligonucleotides, protein kinase C (PKC), therapeutic target, cell membrane receptors, several signaling cascades, cell cycle arrest, normal mammary cells, matrix metalloproteinases (MMP)
Current Pharmaceutical Biotechnology
Title: The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Volume: 12 Issue: 11
Author(s): F. Coluccio Leskow, M. A. Krasnapolski and A. J. Urtreger
Affiliation:
Keywords: Cancer, clinical trials, PKC, tumor promotion, malignant transformation, specific pharmacological agents, anti-sense oligonucleotides, protein kinase C (PKC), therapeutic target, cell membrane receptors, several signaling cascades, cell cycle arrest, normal mammary cells, matrix metalloproteinases (MMP)
Abstract: In the last years, PKC has become an attractive target for the treatment of cancer patients given its widely described role in carcinogenesis and tumor promotion. Despite the extensive research conducted on these phorbol ester receptors there is only limited knowledge about the contribution of each individual PKC isozyme in malignant transformation, mainly due to the different roles of each isozyme and their tissue-specificity. This diversity provides the unique opportunity to develop specific pharmacological agents, but the complex nature of the signaling pathways activated by different PKCs challenges selective drug therapies. Currently, several classes of PKC inhibitors including small molecule kinase inhibitors, biologic modulators, and anti-sense oligonucleotides are being evaluated for the treatment of different cancers where PKC isozymes were found to be deregulated as lung, colon, skin, prostate, and breast malignancies. In this article we will review which PKC isoforms are deregulated in different human cancers and summarize the mechanism of action of some of the major PKC modulators, analyzing the strengths and weaknesses of each one in the clinical setting.
Export Options
About this article
Cite this article as:
Coluccio Leskow F., A. Krasnapolski M. and J. Urtreger A., The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376950
DOI https://dx.doi.org/10.2174/138920111798376950 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma
Current Pharmaceutical Design Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets AKT/GSK-3 Pathway Targeting; Botanicals and Bioactive Compounds with Anticancer Activities
Current Pharmaceutical Design Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Current Cancer Therapy Reviews A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Non-coding RNA-Encoded Peptides/Proteins in Human Cancer: The Future for Cancer Therapy
Current Medicinal Chemistry ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry The Application of Peptides in Glioma: A Novel Tool for Therapy
Current Pharmaceutical Biotechnology dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?
Current Molecular Medicine Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters